Developer docs
API playgroundTry for free, no card

Search company profiles

Jellagen

Full company profile

uuid0002fla

Namestring
Jellagen
Legal namestring
Jellagen Pty Ltd
Websiteurl
jellagen.co.uk
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Jellagen is a privately held UK medtech company founded in 2013 and incorporated in 2015, headquartered at a 10,000 square-foot ISO 13485:2016 certified R&D, manufacturing, and commercial facility in Cardiff, Wales. The company develops and manufactures medical-grade Collagen Type 0 (Type Zero), a fibrillar collagen extracted from the jellyfish Rhizostoma pulmo via a proprietary process that preserves the triple helix structure and achieves batch-to-batch amino acid consistency of approximately 0.2%. Designated "Type 0" because it predates mammalian collagens by approximately 600 million years, the product is positioned as a non-mammalian, non-immunogenic, pro-angiogenic alternative to bovine, porcine, and rodent collagens, free from prion and disease transmission risks.

The product platform spans medical device formats (micronized powder wound dressings, scaffolds, films, sponges, hydrogels), research products (Collagen Type 0 BioINK for 3D bioprinting co-developed with Copner Biotech), and the JellaGel sub-brand for extracellular matrix applications, targeting advanced wound care, orthopaedics, medical device manufacturers, research and life sciences, and specialist medical applications. The company has built an evidence base through 15+ peer-reviewed publications and collaborations with Mayo Clinic, NPL, Cellaria, and Copner Biotech, and holds a US patent for combined Nitric Oxide and Collagen delivery.

Jellagen monetizes through direct B2B sales to enterprise healthcare and medical device customers under a quote-based pricing model, licensing and co-development revenue with strategic partners, and — since February 2026 — exclusive North American distribution rights held by Royal Biologics, with the partner's CEO joining Jellagen's board. The go-to-market combines enterprise field sales led by CEO Thomas-Paul Descamps, an international distributor network, and content-driven marketing through scientific publications, whitepapers, and industry events. The company is pre-commercial or early-revenue, with cumulative funding of approximately £18M+ across multiple rounds since 2016 and a small team of 1–10 employees.

Short descriptiontext

Jellagen is a UK medtech company that manufactures medical-grade Collagen Type 0, a jellyfish-derived fibrillar collagen biomaterial, supplying advanced wound care, orthopaedic, 3D bioprinting, and regenerative medicine applications to enterprise healthcare and medical device customers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCardiff, United Kingdom
HQ citystring
Cardiff
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical-grade collagen, wound care biomaterials, tissue engineering materials, jellyfish collagen, regenerative medicine biomaterials
Industry4 codes
PRIMARYAFAJAHAD
Marine & Aquatic Protein Ingredients (Fish Protein, Shellfish Protein, Fish Collagen)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAJAMAG
Gelatin & Animal-Derived Hydrocolloids (Gelatin, Collagen, Isinglass)
Agriculture & Food Production/Food Ingredients & Additives/Texturizers (Thickeners & Stabilizers)
SECONDARYAFAJAHAB
Animal-Derived Protein Ingredients (Egg, Collagen/Gelatin, Blood/Plasma Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYCRADAOAJ
Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Medical Biomaterials
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical-Grade Collagen Type 0 Product Sales
TypeOne Time License
Description

Jellagen manufactures and sells medical-grade Collagen Type 0 biomaterials in various formulations (liquid, powder, films, sponges, hydrogels, bioinks) to healthcare providers, medical device companies, and research institutions for tissue engineering, wound healing, and regenerative medicine applications.

jellagen.co.uk
2Licensing and Co-Development Revenue
TypeLicensing Royalties
Description

Royal Biologics partnership includes exclusive North American rights to Collagen Type Zero products. Jellagen co-develops wound matrices and implantable regenerative solutions, generating revenue through licensing fees, milestone payments, and product royalties from commercial partners.

prnewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1JellaGel
Description

Extracellular matrix product derived from jellyfish Collagen Type 0 for medical applications and biological research.

jellagen.co.uk
Core offering1 text field

Jellagen manufactures and sells medical-grade Collagen Type 0, a fibrillar collagen biomaterial derived from the jellyfish Rhizostoma pulmo. The proprietary extraction process maintains the characteristic triple helix structure, producing non-immunogenic, non-mammalian collagen formulated as liquids, powders, films, sponges, hydrogels, and bioinks for wound care, tissue engineering, and regenerative medicine applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • >45% bone growth in cranial wound model with Collagen Type 0 vs. 9% in untreated control group
+5 more records
Product overview1 text field

Jellagen operates as a single unified product platform centered on Collagen Type 0, a jellyfish-derived collagen biomaterial. The core product serves as the foundation for multiple product lines including medical devices (Micronized Collagen Type 0 Powder for wound care, wound dressings), research products (BioINK for 3D bioprinting, scaffolds for bone/orthopaedic applications), and the JellaGel™ sub-brand for extracellular matrix applications. All products derive from the company's proprietary Collagen Type 0 platform extracted from Rhizostoma pulmo jellyfish, offering a non-mammalian alternative to traditional collagen sources for tissue engineering and regenerative medicine.

Product and service6 records
1Collagen Type 0
CategoryMedical Biomaterials
Description

A chemically ancient, medical-grade fibrillar collagen derived from jellyfish (Rhizostoma pulmo) for tissue engineering and regenerative medicine. Non-mammalian, non-immunogenic, pro-angiogenic, and pro-tissue neogenic; free from disease and prion risks associated with mammalian collagen sources. Available in multiple formulations.

2Micronized Collagen Type 0 Powder
CategoryMedical Devices
Description

A patented, micronized powder form of Collagen Type 0 intended to be applied as powder or paste for wound care applications. Provides intimate contact with all areas of the wound bed including irregular, tunnelled, or undermined wounds. Designed for advanced wound care providers treating chronic wounds, diabetic ulcers, and non-healing wounds.

3JellaGel
CategoryMedical Biomaterials
Description

Extracellular matrix type 0 product derived from jellyfish collagen, representing Jellagen's versatile product pipeline for medical applications and biological research, including tissue engineering. Featured in publication with NPL and established as a branded product line.

4Collagen Type 0 BioINK
CategoryResearch Products / Bioinks
Description

A novel Collagen Type 0 bio-ink formulation for 3D bioprinting applications, developed with Copner Biotech's GRAPE-S1 technology platform. Formulated with rheological properties enabling creation of complex 3D tissue architectures for research and tissue engineering applications.

5Collagen Type 0 Scaffolds
CategoryResearch Products
Description

Collagen scaffolds for bone regeneration and orthopaedic applications, providing biocompatibility and adhesive properties for cell culture and bone tissue engineering applications. Used by medical device companies and orthopaedic researchers.

6Collagen Type 0 Wound Dressing
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Royal Biologics announced a strategic partnership and investment with UK-based Jellagen to commercialize Collagen Type Zero in North America. Royal Biologics gains exclusive North American rights and will co-develop wound matrices and implantable regenerative solutions. Salvatore Leo, CEO of Royal Biologics, joins Jellagen's board as strategic commercialization lead. This partnership positions Royal Biologics as the first U.S. company to introduce jellyfish-derived collagen, creating a category-defining product line in biologics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-12
Description

Jellagen and NPL collaborated on research published in Materials Today Bio demonstrating further jellyfish Collagen Type 0 as the foundation for a range of new medical applications and to support new biological research. The collaboration established Collagen Type 0 and JellaGel as a versatile product pipeline.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

Copner Biotech (Lead) and Jellagen were awarded £431,142 Innovate UK funding to develop a next-generation 3D Inkjet bioprinting platform with a novel Collagen Type 0 BioINK formulation. The 19-month project is part of Copner Biotech's roadmap to establish a bioprinting centre of excellence in Wales, UK.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-29
Description

Jellagen and Copner Biotech completed a world-first SMART Cymru-funded project developing a next-generation bioprinting system and bio-ink using Jellagen's jellyfish-derived Collagen Type 0 combined with Copner Biotech's GRAPE-S1 bioprinter. The project successfully demonstrated printing of structures <100 microns in diameter using Collagen Type 0 as a bioink platform.

5Cellaria Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-13
Description

Jellagen partnered with Cellaria Inc. to offer a paradigm shift in collagen chemistry to develop next-generation models for cancer research. This partnership leverages Jellyfish Collagen Type 0 as a superior matrix for 3D cancer cell culture models.

jellagen.co.uk
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Jellagen established development collaborations with Mayo Clinic in the US to investigate and corroborate findings on Collagen Type 0 for regenerative medicine applications. Mayo Clinic is featured as a collaborator logo on the company website.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Advanced BioMatrix
TypeDirect peer
Description

US-based specialist in collagen, hydrogel, and extracellular matrix products for 3D cell culture, tissue engineering, and research applications. Comparable niche player focused on collagen-based biomaterials for research and regenerative medicine, similar customer profile (academic researchers, biotech R&D).

TypeBroad incumbent
Description

Global leader in gelatin and collagen peptides for pharmaceutical, food, and biomedical applications. Comparable to Jellagen on collagen chemistry and biomedical applications but at vastly larger scale and broader portfolio; represents the established incumbent Jellagen must displace in medical-grade collagen supply.

TypeBroad incumbent
Description

US-listed regenerative medicine company specializing in advanced wound care (skin substitutes, amniotic membranes) and surgical biologics. Broad incumbent in Jellagen's primary addressable segment (advanced wound care); both compete for the same clinician formulary slots and CMS reimbursement.

4Gelita
TypeBroad incumbent
Description

German-headquartered global manufacturer of collagen peptides and gelatin for health, nutrition, and pharmaceutical/biomedical markets. Broad incumbent in the collagen/biomaterial space; comparable product chemistry (gelatin/collagen hydrolysates) but operates at commodity scale rather than Jellagen's specialty medical-grade positioning.

TypeDirect peer
Description

Swedish 3D bioprinting and biofabrication company providing bioinks, bioprinters, and tissue engineering solutions. Directly comparable on the bioink and 3D bioprinting side of Jellagen's Collagen Type 0 BioINK platform; both target researchers and pharma with cell culture and tissue model solutions.

TypeBroad incumbent
Description

US-listed regenerative medicine company focused on wound care, surgical recovery, and orthopedics using placental tissue allografts. Broad incumbent in the advanced wound care space where Jellagen's micronized collagen powder is positioned; competes for the same CMS-reimbursed wound care channels reshaped by the 2024 reimbursement reset.

TypeDirect peer
Description

Israel-based biotech producing recombinant human collagen (from tobacco plants) for regenerative medicine, wound healing, and 3D bioprinting. Closest direct peer to Jellagen: both develop non-mammalian collagen platforms targeting tissue engineering, wound care, and bioink applications with comparable regulatory and clinical pathways.

TypeBroad incumbent
Description

UK-listed specialty chemicals company with significant life sciences and biomedical materials business including collagen-derived ingredients for wound care, dermal, and tissue engineering. Broad incumbent with comparable end-markets and customer overlap (medical device OEMs, pharma).

TypeBroad incumbent
Description

US-listed medical technology company with leadership positions in regenerative tissue technologies (collagen-based wound care, dermal matrices, dural repair) and orthopedic implants. Broad incumbent; significant overlap with Jellagen on collagen biomaterials for wound care, orthopedics, and implantable regenerative solutions.

TypeDirect peer
Description

UK-based medical-grade collagen specialist supplying biomaterials for tissue repair, regenerative medicine, and implantable devices. Directly comparable to Jellagen on product (medical-grade collagen), customer base (medical device OEMs), and regulatory pathway; both serve wound care, orthopedics, and cardiac applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jellagen

Medical Biomaterialsjellagen.co.uk

Jellagen is a UK medtech company that manufactures medical-grade Collagen Type 0, a jellyfish-derived fibrillar collagen biomaterial, supplying advanced wound care, orthopaedic, 3D bioprinting, and regenerative medicine applications to enterprise healthcare and medical device customers worldwide.

What Jellagen does

Jellagen is a privately held UK medtech company founded in 2013 and incorporated in 2015, headquartered at a 10,000 square-foot ISO 13485:2016 certified R&D, manufacturing, and commercial facility in Cardiff, Wales. The company develops and manufactures medical-grade Collagen Type 0 (Type Zero), a fibrillar collagen extracted from the jellyfish Rhizostoma pulmo via a proprietary process that preserves the triple helix structure and achieves batch-to-batch amino acid consistency of approximately 0.2%. Designated "Type 0" because it predates mammalian collagens by approximately 600 million years, the product is positioned as a non-mammalian, non-immunogenic, pro-angiogenic alternative to bovine, porcine, and rodent collagens, free from prion and disease transmission risks.

The product platform spans medical device formats (micronized powder wound dressings, scaffolds, films, sponges, hydrogels), research products (Collagen Type 0 BioINK for 3D bioprinting co-developed with Copner Biotech), and the JellaGel sub-brand for extracellular matrix applications, targeting advanced wound care, orthopaedics, medical device manufacturers, research and life sciences, and specialist medical applications. The company has built an evidence base through 15+ peer-reviewed publications and collaborations with Mayo Clinic, NPL, Cellaria, and Copner Biotech, and holds a US patent for combined Nitric Oxide and Collagen delivery.

Jellagen monetizes through direct B2B sales to enterprise healthcare and medical device customers under a quote-based pricing model, licensing and co-development revenue with strategic partners, and — since February 2026 — exclusive North American distribution rights held by Royal Biologics, with the partner's CEO joining Jellagen's board. The go-to-market combines enterprise field sales led by CEO Thomas-Paul Descamps, an international distributor network, and content-driven marketing through scientific publications, whitepapers, and industry events. The company is pre-commercial or early-revenue, with cumulative funding of approximately £18M+ across multiple rounds since 2016 and a small team of 1–10 employees.

Jellagen firmographics

Firmographics
Name
Jellagen
Legal name
Jellagen Pty Ltd
Website
https://jellagen.co.uk
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Jellagen is a UK medtech company that manufactures medical-grade Collagen Type 0, a jellyfish-derived fibrillar collagen biomaterial, supplying advanced wound care, orthopaedic, 3D bioprinting, and regenerative medicine applications to enterprise healthcare and medical device customers worldwide.
Ownership category
akta.pro rank

Jellagen industry classification

Industry
Product category
Medical Biomaterials
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYAFAJAHAD
Marine & Aquatic Protein Ingredients (Fish Protein, Shellfish Protein, Fish Collagen)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAJAMAG
Gelatin & Animal-Derived Hydrocolloids (Gelatin, Collagen, Isinglass)
Agriculture & Food Production/Food Ingredients & Additives/Texturizers (Thickeners & Stabilizers)
SECONDARYAFAJAHAB
Animal-Derived Protein Ingredients (Egg, Collagen/Gelatin, Blood/Plasma Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYCRADAOAJ
Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids)

Keywords

  • Medical-grade collagen
  • Wound care biomaterials
  • Tissue engineering materials
  • Jellyfish collagen
  • Regenerative medicine biomaterials

Where Jellagen is headquartered

Location

Headquarters

HQ city
Cardiff
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Jellagen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical-Grade Collagen Type 0 Product Sales: Jellagen manufactures and sells medical-grade Collagen Type 0 biomaterials in various formulations (liquid, powder, films, sponges, hydrogels, bioinks) to healthcare providers, medical device companies, and research institutions for tissue engineering, wound healing, and regenerative medicine applications.
  2. Licensing and Co-Development Revenue: Royal Biologics partnership includes exclusive North American rights to Collagen Type Zero products. Jellagen co-develops wound matrices and implantable regenerative solutions, generating revenue through licensing fees, milestone payments, and product royalties from commercial partners.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Jellagen product offering

Product offering

Core offering

Jellagen manufactures and sells medical-grade Collagen Type 0, a fibrillar collagen biomaterial derived from the jellyfish Rhizostoma pulmo. The proprietary extraction process maintains the characteristic triple helix structure, producing non-immunogenic, non-mammalian collagen formulated as liquids, powders, films, sponges, hydrogels, and bioinks for wound care, tissue engineering, and regenerative medicine applications.

Product overview

Jellagen operates as a single unified product platform centered on Collagen Type 0, a jellyfish-derived collagen biomaterial. The core product serves as the foundation for multiple product lines including medical devices (Micronized Collagen Type 0 Powder for wound care, wound dressings), research products (BioINK for 3D bioprinting, scaffolds for bone/orthopaedic applications), and the JellaGel™ sub-brand for extracellular matrix applications. All products derive from the company's proprietary Collagen Type 0 platform extracted from Rhizostoma pulmo jellyfish, offering a non-mammalian alternative to traditional collagen sources for tissue engineering and regenerative medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • JellaGel: Extracellular matrix product derived from jellyfish Collagen Type 0 for medical applications and biological research.

Products and services

  • Collagen Type 0 A chemically ancient, medical-grade fibrillar collagen derived from jellyfish (Rhizostoma pulmo) for tissue engineering and regenerative medicine. Non-mammalian, non-immunogenic, pro-angiogenic, and pro-tissue neogenic; free from disease and prion risks associated with mammalian collagen sources. Available in multiple formulations.
  • Micronized Collagen Type 0 Powder A patented, micronized powder form of Collagen Type 0 intended to be applied as powder or paste for wound care applications. Provides intimate contact with all areas of the wound bed including irregular, tunnelled, or undermined wounds. Designed for advanced wound care providers treating chronic wounds, diabetic ulcers, and non-healing wounds.
  • JellaGel Extracellular matrix type 0 product derived from jellyfish collagen, representing Jellagen's versatile product pipeline for medical applications and biological research, including tissue engineering. Featured in publication with NPL and established as a branded product line.
  • Collagen Type 0 BioINK A novel Collagen Type 0 bio-ink formulation for 3D bioprinting applications, developed with Copner Biotech's GRAPE-S1 technology platform. Formulated with rheological properties enabling creation of complex 3D tissue architectures for research and tissue engineering applications.
  • Collagen Type 0 Scaffolds Collagen scaffolds for bone regeneration and orthopaedic applications, providing biocompatibility and adhesive properties for cell culture and bone tissue engineering applications. Used by medical device companies and orthopaedic researchers.
  • Collagen Type 0 Wound Dressing

Quantifiable outcome

  • >45% bone growth in cranial wound model with Collagen Type 0 vs. 9% in untreated control group
  • +5 more outcomes

Companies that use Jellagen

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Jellagen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Jellagen partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship and core.

  • Royal BiologicsflagshipStrategic or Co-development Partner · 24 February 2026Royal Biologics announced a strategic partnership and investment with UK-based Jellagen to commercialize Collagen Type Zero in North America. Royal Biologics gains exclusive North American rights and will co-develop wound matrices and implantable regenerative solutions. Salvatore Leo, CEO of Royal Biologics, joins Jellagen's board as strategic commercialization lead. This partnership positions Royal Biologics as the first U.S. company to introduce jellyfish-derived collagen, creating a category-defining product line in biologics.
  • National Physical Laboratory (NPL)coreStrategic or Co-development Partner · 12 September 2023Jellagen and NPL collaborated on research published in Materials Today Bio demonstrating further jellyfish Collagen Type 0 as the foundation for a range of new medical applications and to support new biological research. The collaboration established Collagen Type 0 and JellaGel as a versatile product pipeline.
  • Copner Biotech LtdcoreStrategic or Co-development Partner · 1 November 2022Copner Biotech (Lead) and Jellagen were awarded £431,142 Innovate UK funding to develop a next-generation 3D Inkjet bioprinting platform with a novel Collagen Type 0 BioINK formulation. The 19-month project is part of Copner Biotech's roadmap to establish a bioprinting centre of excellence in Wales, UK.
  • Copner Biotech LtdcoreStrategic or Co-development Partner · 29 September 2022Jellagen and Copner Biotech completed a world-first SMART Cymru-funded project developing a next-generation bioprinting system and bio-ink using Jellagen's jellyfish-derived Collagen Type 0 combined with Copner Biotech's GRAPE-S1 bioprinter. The project successfully demonstrated printing of structures <100 microns in diameter using Collagen Type 0 as a bioink platform.
  • Cellaria Inc.coreStrategic or Co-development Partner · 13 November 2021Jellagen partnered with Cellaria Inc. to offer a paradigm shift in collagen chemistry to develop next-generation models for cancer research. This partnership leverages Jellyfish Collagen Type 0 as a superior matrix for 3D cancer cell culture models.
  • Mayo CliniccoreStrategic or Co-development PartnerJellagen established development collaborations with Mayo Clinic in the US to investigate and corroborate findings on Collagen Type 0 for regenerative medicine applications. Mayo Clinic is featured as a collaborator logo on the company website.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Jellagen competitors and assessment

Company assessment

Direct peers

  • Advanced BioMatrix: US-based specialist in collagen, hydrogel, and extracellular matrix products for 3D cell culture, tissue engineering, and research applications. Comparable niche player focused on collagen-based biomaterials for research and regenerative medicine, similar customer profile (academic researchers, biotech R&D).
  • BICO (formerly Cellink): Swedish 3D bioprinting and biofabrication company providing bioinks, bioprinters, and tissue engineering solutions. Directly comparable on the bioink and 3D bioprinting side of Jellagen's Collagen Type 0 BioINK platform; both target researchers and pharma with cell culture and tissue model solutions.
  • CollPlant Biotechnologies: Israel-based biotech producing recombinant human collagen (from tobacco plants) for regenerative medicine, wound healing, and 3D bioprinting. Closest direct peer to Jellagen: both develop non-mammalian collagen platforms targeting tissue engineering, wound care, and bioink applications with comparable regulatory and clinical pathways.
  • Regenity Biosciences (formerly Collagen Solutions): UK-based medical-grade collagen specialist supplying biomaterials for tissue repair, regenerative medicine, and implantable devices. Directly comparable to Jellagen on product (medical-grade collagen), customer base (medical device OEMs), and regulatory pathway; both serve wound care, orthopedics, and cardiac applications.

Broad incumbents

  • Rousselot (Darling Ingredients): Global leader in gelatin and collagen peptides for pharmaceutical, food, and biomedical applications. Comparable to Jellagen on collagen chemistry and biomedical applications but at vastly larger scale and broader portfolio; represents the established incumbent Jellagen must displace in medical-grade collagen supply.
  • Organogenesis Holdings: US-listed regenerative medicine company specializing in advanced wound care (skin substitutes, amniotic membranes) and surgical biologics. Broad incumbent in Jellagen's primary addressable segment (advanced wound care); both compete for the same clinician formulary slots and CMS reimbursement.
  • Gelita: German-headquartered global manufacturer of collagen peptides and gelatin for health, nutrition, and pharmaceutical/biomedical markets. Broad incumbent in the collagen/biomaterial space; comparable product chemistry (gelatin/collagen hydrolysates) but operates at commodity scale rather than Jellagen's specialty medical-grade positioning.
  • MiMedx Group: US-listed regenerative medicine company focused on wound care, surgical recovery, and orthopedics using placental tissue allografts. Broad incumbent in the advanced wound care space where Jellagen's micronized collagen powder is positioned; competes for the same CMS-reimbursed wound care channels reshaped by the 2024 reimbursement reset.
  • Croda International: UK-listed specialty chemicals company with significant life sciences and biomedical materials business including collagen-derived ingredients for wound care, dermal, and tissue engineering. Broad incumbent with comparable end-markets and customer overlap (medical device OEMs, pharma).
  • Integra LifeSciences: US-listed medical technology company with leadership positions in regenerative tissue technologies (collagen-based wound care, dermal matrices, dural repair) and orthopedic implants. Broad incumbent; significant overlap with Jellagen on collagen biomaterials for wound care, orthopedics, and implantable regenerative solutions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Jellagen social profiles

Digital presence

Jellagen compliance and trust

Trust signal

Compliance1 record

Jellagen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jellagen leadership team

Management profile

Number of profiles

Profiles7 records

Jellagen funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jellagen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jellagen

What does Jellagen do?

Jellagen manufactures and sells medical-grade Collagen Type 0, a fibrillar collagen biomaterial derived from the jellyfish Rhizostoma pulmo. The proprietary extraction process maintains the characteristic triple helix structure, producing non-immunogenic, non-mammalian collagen formulated as liquids, powders, films, sponges, hydrogels, and bioinks for wound care, tissue engineering, and regenerative medicine applications.

Is Jellagen a public or private company?

Jellagen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Jellagen founded?

Jellagen was founded in 2015. It employs 11 to 50 people.

Where is Jellagen based?

Jellagen is headquartered in Cardiff, United Kingdom, in the Europe region.

How does Jellagen make money?

Two revenue lines are on record. Medical-Grade Collagen Type 0 Product Sales are the primary driver. The others are licensing and Co-Development Revenue.

Who are Jellagen's main competitors?

Direct peers on record are Advanced BioMatrix, BICO (formerly Cellink), CollPlant Biotechnologies and Regenity Biosciences (formerly Collagen Solutions). Broad incumbents are Rousselot (Darling Ingredients), Organogenesis Holdings, Gelita, MiMedx Group, Croda International and Integra LifeSciences.

Does Jellagen have an API?

No public API is recorded for Jellagen.

What industry is Jellagen in?

Jellagen's product category is Medical Biomaterials. Its primary akta.pro industry code is AFAJAHAD, Marine & Aquatic Protein Ingredients (Fish Protein, Shellfish Protein, Fish Collagen), with a secondary code of AFAJAMAG, Gelatin & Animal-Derived Hydrocolloids (Gelatin, Collagen, Isinglass). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRoyal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine MarketRoyal Biologics announced a strategic partnership and investment with UK-based Jellagen Ltd to commercialize Collagen Type Zero, a jellyfish-derived regenerative biomaterial, in North American markets. Under the agreement, Royal Biologics gains exclusive North American rights and will co-develop wound matrices and implantable regenerative solutions, while CEO Salvatore Leo joins Jellagen's board as strategic commercialization lead. The partnership positions Royal Biologics as the first U.S. company to introduce jellyfish-derived collagen, creating what both companies call a category-defining product line in biologics.BusinessCloudJellyfish tech firm ‘to revolutionise regenerative medicine’Jellagen, a jellyfish-derived collagen biomaterials firm, closed an £8.7 million Series A round. The funding will support development of Collagen Type 0, which the company claims avoids disease and virus transfer risks from mammalian sources. The company plans to advance its product development toward human trials and regulatory filing.BusinessCloudJellyfish tech firm ‘to revolutionise regenerative medicine’Jellagen, a jellyfish-derived collagen biomaterials firm, closed an £8.7 million Series A round. The funding will support development of Collagen Type 0, which the company claims avoids disease risks from mammalian sources, and advance product development toward human trials and regulatory filing.BusinessCloudJellyfish tech firm ‘to revolutionise regenerative medicine’Jellagen, a jellyfish-derived collagen biomaterials firm, closed an £8.7 million Series A round. The funding will support development of Collagen Type 0 and advance product development toward human trials and regulatory filing. The company cites preclinical superiority over mammalian collagen and collaborations with Mayo Clinic and others.FinSMEsJellagen Closes £8.7M Series A FundingJellagen, a Cardiff-based biotech company, has closed an £8.7 million Series A funding round led by Cardiff Capital Region, Development Bank of Wales, and Thai Union Group PCL. The company plans to utilize these funds to accelerate the medical development of its jellyfish-derived Collagen Type 0 biomaterial and advance its program toward human trials and regulatory filing.JellagenJellagen closes £8.7m Series A funding round to accelerate development of Collagen Type 0 and revolutionise regenerative medicineJellagen has closed an £8.7 million Series A funding round to accelerate the development of Collagen Type 0, a jellyfish-derived biomaterial for regenerative medicine and tissue reconstruction. The investment includes new backing from Cardiff Capital Region, Development Bank of Wales, and Thai Union Group PCL, alongside existing shareholders. This capital will support safety data generation and prototype validation, moving the company closer to human trials and regulatory filings.PR NewswireJellagen Ltd's Jellyfish Collagen 3D Systems Support Ovarian Cancer Cell Line Proliferation, Confirming Suitability for Advanced Cell Culturing ApplicationsA study published in Frontiers in Bioengineering and Biotechnology has demonstrated that jellyfish collagen from R. Pulmo (Jellagen®) provides a reliable in vitro microenvironment for the proliferation and migration of ovarian cancer cell lines (OvCa.3 and SKOV.3). The collaborative research, conducted by Swansea University, National University of Ireland Galway, and Jellagen Ltd, was funded through the Celtic Advanced Life Science Innovation Network to explore sustainable alternatives to mammalian-derived collagen. Industry experts note that this development aligns with FDA and EPA goals to reduce and eliminate animal testing by 2035, highlighting the growing demand for non-animal-derived biomaterials in research.FinSMEsJellagen Receives £3.8M in FundingJellagen, a Cardiff-based marine biotechnology firm, raised £3.8M in funding led by Newable Private Investing, the Development Bank of Wales, and angel investors. The company will use the funds to accelerate sales of its jellyfish-based medicine, expand its management team, and strengthen its intellectual property portfolio.BusinessCloudJellyfish biotech firm boosted by £3.8m in fundingCardiff-based Jellagen raised £3.8m in funding to accelerate sales of its jellyfish collagen products. The firm, founded in 2013, will use the investment to expand into cell culture and regenerative medicine markets. The funding was led by Newable Private Investing and the Development Bank of Wales.FinSMEsJellagen Completes £1.53M in Equity FundingJellagen, a UK-based medical-technology company, completed a £1.53m equity funding round led by angels in Medcity/London Business Angels and Finance Wales. The funds will expand collagen processing capacity, establish a Quality Management System, and recruit up to six new staff over two years.